Skip to main content
HANGZHOU AGS MEDTECH CO.,LTD logo

HANGZHOU AGS MEDTECH CO.,LTD — Investor Relations & Filings

Ticker · 688581 ISIN · CNE100005ZF0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2025-04-22 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688581

About HANGZHOU AGS MEDTECH CO.,LTD

http://www.bioags.com/en/index.aspx

Hangzhou AGS MedTech Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical instruments, primarily focusing on endoscopic accessories. The product portfolio encompasses a comprehensive range of disposable devices for gastrointestinal and respiratory interventions, including biopsy forceps, hemoclips, injection needles, polypectomy snares, and guide wires. The company integrates advanced manufacturing processes with rigorous quality management systems, adhering to international standards such as ISO 13485, CE, and FDA. By providing high-precision diagnostic and therapeutic tools, the organization supports clinical procedures in gastroenterology and pulmonology. Its technical expertise facilitates the delivery of reliable solutions aimed at improving procedural outcomes and patient safety in global healthcare markets.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于杭州安杰思医学科技股份有限公司使用部分暂时闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from CITIC Securities Co., Ltd. acting as the sponsor for Hangzhou Anjiese Medical Technology Co., Ltd. It concerns the use of temporarily idle raised funds for cash management. The document includes specifics about the raised funds, investment projects, cash management purposes, investment products, risk control measures, and approvals by the board and supervisory committee. It also contains the sponsor's verification opinion. The document is not a general announcement or a brief notice but a comprehensive verification report related to the use of raised funds. It does not contain financial statements or earnings data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a capital/financing update or a regulatory filing in the general sense. The document is a formal audit/verification report on the use of raised funds, which fits the category of Audit Report / Information (AR). FY 2025
2025-04-22 Chinese
董事会对在任独立董事独立性自查情况的专项意见
Governance Information Classification · 95% confidence The document is a specialized opinion from the board regarding the independence of current independent directors, referencing regulatory requirements from the China Securities Regulatory Commission and Shanghai Stock Exchange rules. It is a governance-related statement about board members' independence, not a full report, financial statement, or announcement of voting results. It does not contain financial data or detailed management discussion. Therefore, it fits best under Governance Information (CGR). The document length is short and focused on governance compliance.
2025-04-22 Chinese
安杰思独立董事提名人声明与承诺-沈梦晖
Board/Management Information Classification · 95% confidence The document is a detailed statement and commitment regarding the nomination of an independent director candidate for a listed company on the Science and Technology Innovation Board (科创板). It includes qualifications, compliance with laws and regulations, independence criteria, and absence of adverse records. This type of document is related to board or management information, specifically about the nomination of a board member. It is not a financial report, audit, earnings release, or regulatory filing. It is not a voting result or proxy solicitation either. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short and focused on nomination, not a full report or announcement of a report publication.
2025-04-22 Chinese
安杰思审计委员会对2024年度会计师事务所行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from the Audit Committee regarding the supervision of the accounting firm for the fiscal year 2024. It includes information about the accounting firm, the audit committee's evaluation of the firm's qualifications and performance, meetings held to discuss audit plans, and the committee's overall assessment of the audit work. The content focuses on the audit process and oversight rather than presenting the full annual financial statements or comprehensive company performance data. It is a standalone audit-related report describing the audit committee's supervisory role and the audit firm's execution of their duties. Therefore, this document fits the category of an Audit Report / Information (AR). The document length is over 5,000 characters and contains substantive content, not just an announcement or certification, so it is not RPA or RNS. FY 2024
2025-04-22 Chinese
安杰思2025年限制性股票激励计划激励对象名单
Share Issue/Capital Change Classification · 95% confidence The document is a list of incentive recipients under a 2025 restricted stock incentive plan for Hangzhou Anjiesi Medical Technology Co., Ltd. It details the number of restricted shares granted to core management and technical personnel, along with notes on the plan's scope and limitations. There is no financial report, earnings data, or regulatory certification. The content is about share-based incentive awards to employees, which relates to share issue or capital changes. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length is short but contains substantive information about share grants, not just an announcement or notice.
2025-04-22 Chinese
安杰思关于参加2024年度科创板医疗器械行业集体业绩说明会暨召开2025年一季度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement from Hangzhou Anjiesi Medical Technology Co., Ltd. about participating in a 2024 annual industry collective performance explanation meeting and holding a 2025 first quarter performance explanation meeting. It specifies the meeting date, time, location, and participation details. The document states that the company plans to release its 2024 annual report and 2025 first quarter report on April 23, 2025, and the meeting is to discuss these results and answer investor questions. The document itself does not contain the actual financial data or detailed report content but serves as a notice for the upcoming investor presentation and performance explanation meeting. The document length is short (1572 characters), and it primarily announces the event and how investors can participate. Therefore, according to the "Menu vs Meal" rule, this is an announcement of an investor presentation or earnings call, not the report itself. The best fitting category is Investor Presentation (IP).
2025-04-17 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.